Day Zero Diagnostics, Boston, MA, USA
DIAGNOSTIC, ID and AST
Whole-genome sequencing and machine learning
Day Zero’s diagnostic system is designed to extract bacterial DNA directly from a patient sample, such as blood, for sequencing, without the need for a time-consuming culture. The company’s proprietary machine-learning algorithm then analyzes the genomic data to identify (ID) the pathogen and determine its antibiotic susceptibility (AST) and resistance profile within hours, allowing physicians to confidently and quickly prescribe the most effective treatment. The system is designed to allow for the simultaneous testing of a broad range of bacterial species and their antibiotic susceptibility instead of just a handful of species, like current molecular diagnostic approaches. The system promises to help physicians treat severe infections with the most effective antibiotic treatment on the first day a patient is admitted to the hospital—day zero—rather than a patient being treated with multiple days of toxic broad-spectrum antibiotics often associated with sepsis.
Current Development Stage: Development
CARB-X Investment: Initial investment of up to $6.2m with potential option payments up to $18.7m.
Initial CARB-X Investment Date: January 1, 2020